Healthcare
Inhibrx Biosciences, Inc.(INBX)
Live Price
Offline$87.01
-4.65% today
1Y Change
+529.55%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $1.89B
- Revenue Growth
- +550.0%
- EPS Growth
- -107.8%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inhibrx Biosciences, Inc. (INBX) is a Healthcare stock with a market cap of $1.89B and listed on NASDAQ. The stock last traded around $87.01 and up 529.5% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +550.0%, EPS growth of -107.8%, a dividend yield of 0.0%. What stands out right now is revenue +550.0%, EPS -107.8%, free cash flow +34.1% with operating margin -10386.5% and ROIC -117.4%. Valuation already assumes a fairly strong business story at price/sales 1451.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines INBX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+550.0% vs +7.6% peer median
Operating Margin
Below sector median
-10386.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +550.0% and EPS is at -107.8%, with operating margin around -10386.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -1.5% | -6.7% | -20.7% |
2026 Mar 19, 2026 | -1.4% | -6.1% | +1.4% | +36.0% |
2025 Nov 14, 2025 | -9.6% | -2.2% | +6.1% | -3.7% |
Benchmark Edge
INBX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INBX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INBX Max Drawdown
-38.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INBX and SPY.
Company Overview
Inhibrx Biosciences, Inc.
NASDAQ Global Market
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
- Leadership
- Mark Paul Lappe
- IPO Date
- Jun 4, 2024
- Employees
- 156
- Street Address
- 11025 North Torrey Pines Road
- Mailing
- La Jolla, CA, 92037
- Region
- La Jolla, CA, US
- Reporting Currency
- USD
- Investor Line
- 858-795-4220
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1451.8
- Price/Book
- 250.4
Growth
- Revenue
- +550.0%
- EPS
- -107.8%
- Free Cash Flow
- +34.1%
Profitability
- Gross Margin
- -91.0%
- Operating Margin
- -10386.5%
- Net Margin
- -10773.5%
- ROE
- -269.6%
- ROIC
- -117.4%
Balance Sheet
- Debt/Equity
- 13.39
- Current Ratio
- 3.93
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.